Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03685552 · ClinicalTrials.gov registry record · NA
Safety Evaluation of a Diet and Nutritional Supplementation Program- Purify 2.0
A NA study, sponsored by Nature's Sunshine Products.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT03685552: Completed NA study, sponsored by Nature's Sunshine Products.
NCT03685552 is a NA study that has completed, run by Nature's Sunshine Products. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03685552, a NA study, has completed, sponsored by Nature's Sunshine Products.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
The study evaluated the safety, tolerability and acceptability of a lifestyle modification program with nutritional supplementation designed to restore balance to healthy bowel function in generally healthy subjects
Primary Outcome
Data collection at individual and group visits and physician interviews at individual visits (baseline, week 1, week 2 and week 4) will be used to assess participants for treatment-related adverse events. Subjects with ongoing AEs may be followed for an additional 4 weeks at the discretion of the PI.
Interventions
- OTHER Prog: Purify-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-08-03 |
| Est. Completion | 2017-09-13 |
| Phase | NA |
What the finished NCT03685552 record still lists
NCT03685552 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Prog: Purify-2 is the first listed.
NCT03685552 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03685552 about?
NCT03685552 is a clinical study titled "Safety Evaluation of a Diet and Nutritional Supplementation Program- Purify 2.0". The study evaluated the safety, tolerability and acceptability of a lifestyle modification program with nutritional supplementation designed to restore balance to healthy bowel function in generally healthy subjects
What is the current status of trial NCT03685552?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2017-08-03. Estimated completion is 2017-09-13.
What interventions are being tested in trial NCT03685552?
The interventions under investigation include: Prog: Purify-2 (OTHER).
Who is sponsoring clinical trial NCT03685552?
This trial is sponsored by Nature's Sunshine Products, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03685552's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI